Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18 JPY | +5.88% | -5.26% | -21.74% |
Apr. 29 | Poland's Tusk calls prosecutor over potential Orlen scandal | RE |
Apr. 22 | OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024 | CI |
Sales 2022 | 1.15B 7.3M | Sales 2023 | 1.13B 7.18M | Capitalization | 9.05B 57.34M |
---|---|---|---|---|---|
Net income 2022 | -2.57B -16.28M | Net income 2023 | -1.12B -7.08M | EV / Sales 2022 | 9.94 x |
Net cash position 2022 | 1.84B 11.63M | Net cash position 2023 | 1.12B 7.07M | EV / Sales 2023 | 7 x |
P/E ratio 2022 |
-5.03
x | P/E ratio 2023 |
-8.1
x | Employees | 60 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.45% |
1 day | +5.88% | ||
1 week | -5.26% | ||
Current month | -10.00% | ||
1 month | -10.00% | ||
3 months | -10.00% | ||
6 months | -35.71% | ||
Current year | -21.74% |
Managers | Title | Age | Since |
---|---|---|---|
Junichi Shimada
PSD | President | 62 | 21-11-30 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Hatsuo Kato
CHM | Chairman | 80 | 20-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 18 | +5.88% | 4 625 500 |
24-04-30 | 17 | 0.00% | 2,162,000 |
24-04-26 | 17 | -5.56% | 5,666,000 |
24-04-25 | 18 | -5.26% | 3,194,200 |
24-04-24 | 19 | 0.00% | 2,604,900 |
Delayed Quote Japan Exchange, May 01, 2024 at 01:47 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-21.74% | 23.5M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- 4564 Stock